Authors


Iltefat Hamzavi, MD

Latest:

Late-Breaking Data: Upadacitinib for Vitiligo Achieves Skin Repigmentation Through Week 52

Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.


Marian Freedman

Latest:

Does diet really play a role in acne?

For years, teenagers have been told to avoid certain foods to reduce acne. A review article examines the evidence.



Peter Baek

Latest:

An Overview of Argyria

Argyria is a rare dermatologic condition that presents with blue or grey mucocutaneous discoloration following cutaneous exposure or ingestion of silver.


Matthew Reynolds, PA-C

Latest:

Managing aBCC and aCSCC With Cemiplimab: Tips From Matthew Reynolds, PA-C

Reynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.



Robert J. Casquejo, PA-C

Latest:

Looking Ahead: A Conversation Surrounding Closing the Gaps in Plaque Psoriasis Management

Drs Lisa Swanson and Robert J. Casquejo express their optimism for the future of plaque psoriasis management, sharing their vision for expanded treatment approvals in the pediatric population affected by this condition.


Melinda Gooderham, MSc, MD, FRCPC

Latest:

Late-Breaking Data: Long-Term Safety and Efficacy of Delgocitinib Cream for Chronic Hand Eczema

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.


Jeremy D. Sherer, JD

Latest:

Telehealth in 2023: What Physicians Need to Know

Answers to some common questions about providing telehealth services in 2023.


Adelaide A. Hebert, MD, FAAD

Latest:

Final Thoughts on Tapinarof in AD Clinical Trials

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.


Glynis Ablon, MD

Latest:

Glynis Ablon, MD, Previews IMCAS World Congress 2024

Ablon’s session highlights include best practices for hair restoration.


Joel M. Gelfand, MD, MSCE, FAAD

Latest:

Shedding LITE on At-Home Phototherapy Treatment for Psoriasis

Get a sneak peek ahead of AAD about the LITE study’s patient-centered design, routine care integration, and diverse participant inclusion, offering a cost-effective option in psoriasis treatment.


Heidi Anne Duerr, MPH

Latest:

Amy S. Paller, MD: PEDISTAD Trial Explores Bone Health in Children With Atopic Dermatitis

Paller shares early findings from the award winning poster on PEDISTAD trial and its clinical implication for children with atopic dermatitis.



Karan Lal, DO, MS, FAAD

Latest:

Catching Up With Karan Lal, DO, MS FAAD

In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.


Jonathan S Zager, MD, FACS, FSSO

Latest:

Expert Perspectives on BOLT clinical trial data

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.


Nathalie Ly

Latest:

Considerations to Best Serve Transgender Patients Seeking Aesthetic Care

Ronda Farah, MD, and her colleagues reviewed how dermatology providers play an important role in transgender aesthetic care.


Benjamin Lockshin, MD, FAAD

Latest:

Case 2: Expert Opinions on Enhancing Patient Education of Vitiligo Treatment Risks and Benefits

Benjamin Lockshin, MD, FAAD, summarizes the panel's best practices for improving patient education on the risks and benefits of vitiligo treatment. He underscores the importance of establishing and managing expectations for treatment response.


Hilary Baldwin, MD

Latest:

Hilary Baldwin, MD, Discusses Impacts of Isotretinoin Use

Baldwin reviewed inflammatory bowel disease, depression, and pregnancy during the 2023 ARM Yourself With Knowledge webinar.


Courtney Marabella

Latest:

Topical Remetinostat Effective, Tolerable in Basal Cell Carcinoma

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.


Adam Braunscheidel, CFP

Latest:

Tax-Loss Harvesting: An Important Tactic Every Dermatologist Should Consider

To properly execute loss harvesting and reinvestment properly, without running afoul of Internal Revenue Service rules, it is crucial that one works with a professional adviser experienced in these matters.


Elizabeth Swanson, MD

Latest:

Patient Case #3: 32-Year-Old Male With AD

Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.


Giuliana Grossi

Latest:

Severity of Psoriatic Disease Significantly Associated With Risk of Inflammatory Bowel Disease

A recent study identified an association between psoriasis severity and IBD, Crohn disease, and ulcerative colitis.


Amanda L. Michaud, PA-C

Latest:

Tips for Difficult to Control Chronic Spontaneous Urticaria

Amanda L. Michaud, PA-C, shares insights on difficult to control chronic spontaneous urticaria at the ACAAI Annual Scientific Meeting.




Jason Luke, MD, FACP

Latest:

New Long-Term KEYNOTE-716 Data Presented at ASCO 2023

Principal investigator Jason Luke, MD, discusses what the new data means for melanoma treatment moving forward.


Russ Conroy

Latest:

Cancer Vaccine Plus Keytruda Improves Survival Without Relapse in Resected Melanoma

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.


Cameron Santoro

Latest:

Poster Presentations Demonstrate Efficacy of Deuruxolitinib in Patients With Moderate to Severe Alopecia Areata

The data suggests that the medication, which targets specific cellular pathways, promotes hair regrowth in AA with minimal adverse effects.


Lilia Correa-Selm, MD, FAAD, FACMS

Latest:

Expert Perspectives on BOLT clinical trial data

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

© 2024 MJH Life Sciences

All rights reserved.